Showing results (1011-1020 of 1,142) with videos related to
Sort By:
Pageof 115
The New England Journal of Medicine|April 15, 2014
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosisFred Poordad, Christophe Hezode, Roger Trinh, et al.Hepatology (Baltimore, Md.)|March 13, 2024
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case seriesChristopher Dietz-Fricke, Elisabetta Degasperi, Mathias Jachs, et al.Hepatology (Baltimore, Md.)|May 13, 2011
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological responseRoeland Zoutendijk, Jurriën G P Reijnders, Ashley Brown, et al.Critical Care (London, England)|May 13, 2022
Clinical and biochemical endpoints and predictors of response to plasma exchange in septic shock: results from a randomized controlled trialKlaus Stahl, Philipp Wand, Benjamin Seeliger, et al.Plos One|July 18, 2018
No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis BLai Wei, Heiner Wedemeyer, Yun-Fan Liaw, et al.Liver International : Official Journal of the International Association for the Study of the Liver|March 9, 2026
Elevated Polyreactive Immunoglobulin G in Immune-Mediated Liver Injuries With the Need for Immunosuppressive TherapyTheresa Kirchner, George N Dalekos, Kalliopi Zachou, et al.Plos One|October 20, 2010
Generation of human antigen-specific monoclonal IgM antibodies using vaccinated "human immune system" micePablo D Becker, Nicolas Legrand, Caroline M M van Geelen, et al.Plos One|October 11, 2014
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAABenjamin Heidrich, Steffen B Wiegand, Peter Buggisch, et al.Liver International : Official Journal of the International Association for the Study of the Liver|June 18, 2024
Long-term outcome of hepatitis delta in different regions world-wide: Results of the Hepatitis Delta International NetworkAnika Wranke, Cirley Lobato, Emanoil Ceausu, et al.Journal of Hepatology|January 18, 2011
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis CMichael Manns, Stefan Zeuzem, Ajit Sood, et al.Pageof 115